Konomura Keiko, Nagai Hideaki, Akazawa Manabu
Public Health and Epidemiology, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose, Tokyo, 204-8588 Japan.
Center for Pulmonary Diseases, National Hospital Organization Tokyo National Hospital, 3-1-1 Takeoka, Kiyose-shi, Tokyo, 204-8585 Japan.
Pneumonia (Nathan). 2017 Dec 5;9:19. doi: 10.1186/s41479-017-0042-1. eCollection 2017.
This study aimed to estimate the economic burden of community-acquired pneumonia (CAP) among elderly patients in Japan. In addition, the study evaluated the relationship between total treatment cost and CAP risk factors.
An administrative database was searched for elderly patients (≥ 65 years old) who had pneumonia (ICD-10 code: J12-J18) and an antibiotic prescription between 1 June 2014 and 31 May 2015. The all-cause total healthcare costs of outpatient and inpatient CAP episodes were calculated.
This study evaluated data from 29,619 patients with CAP who experienced 14,450 outpatient CAP episodes and/or 20,314 inpatient CAP episodes. The mean ages were 77.5 ± 8.0 years and 81.5 ± 8.2 years among the outpatient and inpatient groups, respectively. The median treatment costs were US$346 (interquartile range: $195-551) per outpatient episode and US$4851 (interquartile range: $3313-7669) per inpatient episode. More severe cases had increased treatment costs at the treating hospitals. Male sex, diabetes, chronic obstructive pulmonary disease, and liver dysfunction were associated with increased total treatment costs, while dementia, dialysis, and rheumatism were associated with high costs of treating a CAP episode.
The economic burden of CAP might be decreased by reducing the number of hospitalizations for mild CAP and the incidence of severe CAP. Therefore, preventative care (e.g. oral hygiene or pneumococcus vaccination) is recommended for patients with related risk factors, such as male sex, older age, diabetes, chronic obstructive pulmonary disease, liver dysfunction, rheumatism, dementia, or dialysis.
本研究旨在估算日本老年患者社区获得性肺炎(CAP)的经济负担。此外,该研究评估了总治疗成本与CAP危险因素之间的关系。
在一个行政数据库中搜索2014年6月1日至2015年5月31日期间患有肺炎(国际疾病分类第十版编码:J12 - J18)且有抗生素处方的老年患者(≥65岁)。计算门诊和住院CAP发作的全因总医疗费用。
本研究评估了29,619例CAP患者的数据,这些患者经历了14,450次门诊CAP发作和/或20,314次住院CAP发作。门诊组和住院组的平均年龄分别为77.5±8.0岁和81.5±8.2岁。每次门诊发作的治疗成本中位数为346美元(四分位间距:195 - 551美元),每次住院发作的治疗成本中位数为4851美元(四分位间距:3313 - 7669美元)。病情越严重,治疗医院的治疗成本越高。男性、糖尿病、慢性阻塞性肺疾病和肝功能障碍与总治疗成本增加相关,而痴呆、透析和风湿病与治疗一次CAP发作的高成本相关。
通过减少轻度CAP的住院次数和严重CAP的发病率,CAP的经济负担可能会降低。因此,建议对具有相关危险因素的患者,如男性、老年、糖尿病、慢性阻塞性肺疾病、肝功能障碍、风湿病、痴呆或透析患者,进行预防性护理(如口腔卫生或肺炎球菌疫苗接种)。